101 Seaport Boulevard, 7th Floor
About Orchard Therapeutics
Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.
Orchard’s portfolio of ex vivo autologous gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first ex vivo autologous gene therapy approved by the EMA in 2016, three advanced registrational studies for metachromatic leukodystrophy (MLD), ADA-SCID and Wiskott-Aldrich syndrome (WAS), clinical programs for X-linked chronic granulomatous disease (X-CGD), transfusion-dependent beta-thalassemia (TDT) and mucopolysaccharidosis type I (MPS-I), as well as an extensive preclinical pipeline.
The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.
Orchard is a publicly traded company (NASDAQ: ORTX) with offices in the UK and the US, including London and Boston.
141 articles with Orchard Therapeutics
11/22/2021With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look.
Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced data published in the New England Journal of Medicine (NEJM) evaluating the safety and efficacy of OTL-203 for the treatment of the Hurler subtype of Mucopolysaccharidosis type I (MPS-IH).
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present and be available for one-on-one meetings at the following virtual investor conferences.
Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates
Orchard Therapeutics today reported financial results for the quarter ended September 30, 2021, as well as recent business updates and upcoming milestones.
Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress
Orchard Therapeutics today announced the acceptance of nine abstracts at the upcoming European Society of Gene & Cell Therapy Congress (ESGCT) taking place virtually from October 19-22.
Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event
Orchard Therapeutics, a global gene therapy leader, will present on the company’s discovery and research efforts in hematopoietic stem cell gene therapy, including an update on the OTL-104 program in development for NOD2 Crohn’s disease, together with overviews of potential new applications in the areas of HSC-generated antigen-specific regulatory T cells and HSC-vectorization of monoclonal antibodies.
Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments
Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively Neuroscience and rare disease leader Leslie Meltzer, Ph.D., promoted to chief medical officer Appointments reinforce company’s strategic focus on innovation in the areas of discovery, clinical development and manufacturing
Orchard Therapeutics, a global gene therapy leader, announced that the company will webcast a virtual R&D Investor Event on Tuesday, September 14, 2021, from 7:00 a.m. to 8:00 a.m. ET.
Orchard Therapeutics Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Sep 07, 2021
Orchard Therapeutics, a global gene therapy leader, announced that the Compensation Committee of Orchard’s Board of Directors approved the grant of non-statutory stock options to four new employees to purchase an aggregate of 278,500 ordinary shares under Orchard’s 2020 Inducement Equity Plan.
Orchard Therapeutics today announced that members of the management team will present and be available for one-on-one meetings at the following investor conferences: Goldman Sachs 11th Annual Biotech Symposium on September 7, 2021
Orchard Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Updates
Orchard Therapeutics, a global gene therapy leader, reported financial results for the quarter ended June 30, 2021, as well as recent business updates and upcoming milestones.
Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema
Orchard Therapeutics announced a strategic collaboration to research, develop, manufacture and commercialize OTL-105, a newly disclosed investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema, a life-threatening rare disorder that causes recurring swelling attacks in the face, throat, extremities and abdomen.
Orchard Therapeutics, a global gene therapy leader, announced several program updates for the company’s portfolio of approved and investigational hematopoietic stem cell gene therapies.
The Rare Disease Company Coalition’s 10 founding members have brought 22 treatments to market and currently have more than 160 rare disease programs in the works.
Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates
Commercial Activities Advancing for Upcoming Launch of LibmeldyTM (atidarsagene autotemcel) for Eligible Patients with Early-onset MLD in Germany
Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID
100% overall survival and ≥95% event-free survival observed at two and three years following one-time treatment withlentiviral HSC gene therapy
Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy
Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders
OTL-203 Achieves Proof of Concept (POC) in MPS-I Hurler Syndrome (MPS-IH); Registrational Trial Planned to Initiate by Year End 2021
- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following virtual investor conferences: Cowen 41 st Annual Healthcare Conference on March 4, 2021, at 10:30 AM ET as part of a panel discussion focused on disorders of the central nervous system
2/15/2021It was a busy week for clinical trial announcements and news. Here’s a look.